HomeFUNDINGCuradigm Announces 1 Million € Funding From BPI France’s Deep Tech Program to Support Development of the Nanoprimer Platform

Curadigm Announces 1 Million € Funding From BPI France’s Deep Tech Program to Support Development of the Nanoprimer Platform

July 17, 2020

Curadigm today announced the receipt of 1 Million € in non-dilutive funding from Deep Tech BPI France for the development of their Nanoprimer technology. The Deep Tech program recognizes biotechnology companies with breakthrough innovation and strong commercial potential.

Curadigm notes the funding award highlights the Nanoprimer’s unique, groundbreaking approach to increasing therapeutic bioavailability and efficacy, which is applicable across multiple drug classes. Curadigm’s selection underscores the novel approach, the strength of the pre-clinical data to-date, as well as the expertise of the team.

The Deep Tech funding initiative is a competitive program that brings together industry experts to evaluate and identify pioneering technologies with significant industry and clinical potential. Curadigm was awarded funding for the development of the Nanoprimer technology, which is designed to redefine the balance between the therapeutic and useless dose of a drug by precisely, but transiently, occupying the clearance pathways within the liver. This approach does not modify the therapeutic at all, rather the Nanoprimer would be administered just before the therapeutic and would act to prevent its rapid clearance, increase bioavailability and subsequent target tissue accumulation.

Curadigm’s Deep Tech funding will support the ongoing pre-clinical development of the Nanoprimer as well as manufacturing scale-up. Curadigm is actively collaborating with companies to evaluate the potential to increase the therapeutic index of their candidate drugs, and recently published work validating the Nanoprimer’s ability to significantly increase the bioavailability and efficacy of RNA therapeutics. Beyond nucleic acid-based treatments, the Nanoprimer technology is broadly applicable across drug classes including nanomedicines and gene editing technologies. Curadigm’s funding will support the advancement of the Nanoprimer program toward IND-readiness.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

Gynesonics Announces FDA Clearance of Next Generation Sonata System

“This clearance brings significant system improvements that expand the location of fibroids that can be treated while allowing the physician to control all aspects of the treatment from within the sterile field,” said Jiayu Chen, Ph.D. Vice President, Engineering and Advanced Technologies at Gynesonics.

Blackrock Neurotech Invests In Groundbreaking Auditory Nerve Implant With University Of Minnesota And MED-EL

The new investment will enable the development and translation of a new ANI through preclinical studies and later, a pilot clinical trial, where the ANI is then implanted in up to three deaf patients.

Jonathan Chapman: New President/CEO of Trividia Health

Chapman said, “I’m honored to join the Trividia team as President and CEO. This organization has a long history of leadership within the healthcare industry as a provider of accurate, accessible, and affordable point-of-care solutions for the management of diabetes.”

SOLOPASS® System (Bedside Neuro-Navigation Device) Receives FDA 510(k) Clearance

inTRAvent’s SOLOPASS® system brings simple, portable, bedside neuro-navigation into the intensive care unit.

Skyhawk Therapeutics Completes New Investment Round

A $133 million round of investment will allow Skyhawk to accelerate development of its novel small molecule RNA-modifying drug candidates into the clinic.

By using this website you agree to accept Medical Device News Magazine Privacy Policy